Thursday, 15 October 2026European Markets

LISGRAFICA Stock Over 33% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of LISGRAFICA (PSI: LIG.LS) rose by a staggering 33.33% in 21 sessions from €0.01 to €0.01 at 01:26 EST on Tuesday, after two consecutive sessions in a row of losses. PSI is jumping 0.79% to €5,769.33, following the last session's downward trend.

LISGRAFICA's last close was €0.01, 35.29% under its 52-week high of €0.01.

About LISGRAFICA

Lisgráfica - Impressão e Artes Gráficas, S.A. provides printing services in Portugal. It prints magazines, newspapers, supplements, catalogs, brochures, and telephone directories. The company was incorporated in 1973 and is headquartered in Agualva-Cacém, Portugal. Lisgrafica-Impressao e Artes Graficas is a subsidiary of Rasográfica - Comércio e Serviços Gráficos, S.A.

Earnings Per Share

As for profitability, LISGRAFICA has a trailing twelve months EPS of €-0.026.

Yearly Top and Bottom Value

LISGRAFICA's stock is valued at €0.01 at 01:26 EST, way above its 52-week high of €0.01.

Volatility

LISGRAFICA's last week, last month's, and last quarter's current intraday variation average was a negative 14.39%, a negative 7.48%, and a positive 22.03%.

LISGRAFICA's highest amplitude of average volatility was 19.95% (last week), 19.98% (last month), and 22.03% (last quarter).

More news about LISGRAFICA (LIG.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com